Why 90% of clinical drug development fails?
Analyses of clinical trial data from 2010 to 2017 show four possible reasons attributed to the 90% clinical failures of drug development: lack of clinical efficacy (40%–50%), unmanageable toxicity (30%), poor drug-like properties (10%–15%), and lack of commercial needs and poor strategic planning (10%)1. This staggering failure rate leads to billions of dollars in sunk costs and prolonged development timelines, making it imperative for pharmaceutical companies to adopt more effective project management strategies.
How can Project Portfolio Management (PPM) Tools Address These Issues?
Planisware’s Enterprise solution helps pharmaceutical companies overcome common drug development challenges by providing real-time visibility into project pipelines, optimizing resource allocation, and enhancing forecasting accuracy. Join us for a session led by Alexis Casciarri from Planisware and Robert Sayegh, Pharma Project Specialist at Guava Project Consulting, on November 12 at 13:00 AEDT / 6 PM CST to see how Planisware can help generate forecasts on complex projects, overlook portfolio health, and improve resource management for better project outcomes.
Key Takeaways:
How to generate a forecast on a complex project.
How to overlook your portfolio and its health.
Improve resource management and project visibility.
1 National Center for Biotechnology Information (NCBI). (2022). Factors Affecting Drug Development Success. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739
